Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin in Immunocompromised Children With Neutropenia
NCT00068471Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2003
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of anidulafungin in fungal infection (2 arms), sponsored by National Cancer Institute. Primary endpoints: Safety and Tolerability up to 28 days, Pharmacokinetics up to 28 days and 1 more. Started Jul 2003; status: completed.
02
Drugs
anidulafungin
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT00068471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068471.